SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group (NBIS) is trending after announcing a $17 billion AI infrastructure deal with Microsoft, significantly exceeding its current market cap. Community discussions revolve around the deal's implications for revenue growth and potential for further partnerships, with some speculating on future price targets and potential acquisitions. The surge in NBIS is also bringing attention to other AI infrastructure plays, as investors anticipate increased demand in the sector.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as the crypto community anticipates a potential breakout, fueled by speculation around upcoming events and positive technical indicators. Discussions center on breaking through resistance levels, particularly the $3 mark, with some eyeing higher targets. A possible ETF approval and Ripple's Swell conference are contributing to the bullish sentiment.

Eightco Holdings, Inc. is a publicly traded holding company, which operates in the consumer products and e-commerce markets, focusing on developing and deploying innovative technology, and capital solutions to empower small to medium-sized businesses. It operates through the North America and Europe geographical segments. The company was founded in 1966 and is headquartered in Easton, PA.

Eightco Holdings Inc

Eightco Holdings ($OCTO) is trending due to a recent surge possibly fueled by news of a $250 million private placement and strategic investment from Bitmine. The community is actively discussing the potential for a short squeeze given the low float, while others are wary of a potential pump and dump scheme. Some investors are comparing $OCTO to other high-flying stocks with crypto treasury strategies.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending with community chatter focused on sales data, potential resistance levels, and upcoming events, including a presentation on Megapacks. Bullish sentiment cites strong China sales and long-term growth potential in energy storage, while bears point to declining market share and concerns about valuation. Discussions also revolve around the company's AI and robotics initiatives and their impact on future revenue.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

Iris Energy Ltd

IREN is trending due to increased interest in AI infrastructure plays, sparked by recent deals in the sector, specifically NBIS. Community members are discussing IREN's potential to secure similar contracts and its advantageous positioning in the AI data center space, with some viewing it as undervalued compared to its peers. The focus is on IREN's capacity, energy sourcing, and potential for significant revenue growth in the rapidly expanding AI market.

Memecoin on Injective taken over by the community.

Nonja

$NONJA.X is trending due to excitement around Injective's ecosystem, particularly the potential approval of a staked $INJ.X ETF, which could drive further investment. The community believes $NONJA.X, as the strongest meme coin on the Injective chain, is positioned for amplified gains. Many community members are discussing the coin's strong community, unique artwork, and a large percentage of the market cap being burned to the liquidity pool.

The mission of the Worldcoin project is to build the world’s largest identity and financial network as a public utility, giving ownership to everyone. A key component of the Worldcoin project is the development of the foundational infrastructure that will be important for a world where AI plays an increasingly large role.  The Worldcoin system revolves around World ID, a privacy-preserving global identity network. World ID enables users to verify their humanness online while maintaining their privacy through zero-knowledge proofs.  Using World ID, individuals will be able to prove that they are a real, unique human to any platform that integrates with the protocol, including to web3 systems, social networking sites, and governmental programs. This will enable fair airdrops or token/NFT sales, provide protection against bots/sybil attacks on social media, and enable the fairer distribution of limited governmental resources. Furthermore, World ID can also enable global democratic processes and novel forms of governance (e.g., via quadratic voting), and it may eventually show a path to AI-funded UBI. The Worldcoin token (WLD), alongside World ID, will let users participate in governing the Worldcoin protocol.   To engage with the Worldcoin protocol, individuals must first download a first wallet app that supports the creation of a World ID. Users visit a physical imaging device called the Orb to get their World ID Orb-verified. Orbs are operated by a network of independent local businesses called Orb Operators. The Orb uses multispectral sensors to verify humanness and uniqueness to issue an Orb-verified World ID, with all images being promptly deleted on-device per default (absent explicit consent to Data Custody). All Orb-verified World IDs holders are entitled to claim recurring grants of free WLD tokens, subject to certain availability restrictions. The WLD token is designed as a utility token with governance properties.

Worldcoin

Worldcoin is trending amidst community discussions around its association with Sam Altman and its potential role in AI identity verification. Some investors express excitement about Altman's involvement and the project's use case, while others voice concerns over privacy, tokenomics, and regulatory hurdles. Speculation about potential partnerships and exchange listings is also fueling interest.

Sentage Holdings, Inc. engages in the financial services, which offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China. The company was founded on September 16, 2019 and is headquartered in Shanghai, China.

Sentage Holdings Inc - Ordinary Shares - Class A

Sentage Holdings Inc

SNTG is trending due to potential short squeeze opportunities, with social media chatter highlighting its low float and comparisons to other recent high-flying stocks like OCTO. Community members are actively discussing its potential for significant gains, while also pointing out its high short interest. Some are drawing attention to the broader sector and its connection to cryptocurrency.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is trending as investors discuss potential upside following a recent dip and solid earnings report, highlighting its position in AI and quantum computing. Community members are debating potential price movements and entry points, with some pointing to the stock's oversold conditions and long-term growth prospects. Despite the positive sentiment, some express frustration with the stock's recent performance compared to its peers.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

OPEN is trending as retail investors discuss recent price action and debate whether the rally will continue. Community members are weighing bullish catalysts like potential rate cuts and a new CEO against bearish sentiment fueled by short sellers, including well-known figures. Some traders are expressing conviction in a potential short squeeze, while others caution against meme stock speculation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Down 21.7% in 4 Weeks, Here's Why Soleno Therapeutics (SLNO) Looks Ripe for a Turnaround 

The heavy selling pressure might have exhausted for Soleno Therapeutics (SLNO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Shares of Soleno Therapeutics (SLNO) slumped 7% on Friday afternoon after Scorpion Capital revealed a short position on the stock, citing risks associated with the company’s drug approved for Prader-Willi syndrome.The shortseller alleged several risks associated with Vykat XR, including high risk of pre-diabetes/diabetes, pulmonary edema, and congestive heart failure. It further alleged that the drug may be at risk of being withdrawn from the market, or new prescriptions may plunge.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SLNO">Soleno</a> trended in the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:1366/124;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_15_at_12_42_29_PM_png_0f8718e0b7.webp" alt="SLNO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on Aug. 15, 2025 | Source: Stocktwits" width="1366" height="124"><figcaption>SLNO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on Aug. 15, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user dismissed the short seller report, citing inconsistencies with public data.<stembedurl>https://stocktwits.com/aristocks/message/625341208</stembedurl>Another believes the stock is a good buy-the-dip candidate.<stembedurl>https://stocktwits.com/CrispDry/message/625323181</stembedurl>Scorpion Capital said in its report that Soleno is reminiscent of the company Zafgen, which announced two patient deaths in 2015 during a trial with an investigational Prader-Willi syndrome drug, leading to discontinuation of the program. Zafgen subsequently merged with Larimar Therapeutics in 2020.“SLNO is at high risk of fading back into obscurity as a zombie biotech that trades near cash - $9/share - round-tripping back to single-digit or penny stock status, as it was a mere ~2.5 years ago when it hit 90 cents,” Scorpion Capital <a target="_blank" rel="noopener noreferrer nofollow" href="https://scorpionreports.s3.us-east-2.amazonaws.com/SLNO1.pdf">said</a> in its report. The firm further alleged that Soleno has “no meaningful assets, pipeline or scientific program, and its only drug is an inferior tablet version of a half-century-old suspension.”Scorpion Capital also stated that it intends to shortly submit an emergency Citizen Petition asking the FDA to request Soleno to conduct a voluntary recall of VYKAT XR from the market.Soleno <a href="https://stocktwits.com/news-articles/markets/equity/soleno-therapeutics-gets-fda-approval-for-prader-willi-syndrome-drug/chJ25DRRbE3">received</a> the U.S. Food and Drug Administration’s approval for Vykat XR extended-release tablets for the treatment of hyperphagia in patients four years of age and older with Prader-Willi syndrome in March and subsequently launched it in April. VYKAT XR is the company’s first commercial product.Prader-Willi syndrome is a rare genetic neurodevelopmental disorder caused by an abnormality in the gene expression on chromosome 15, estimated to occur in one in every 15,000 live births. The disorder is defined by hyperphagia, an intense, persistent sensation of hunger, which could be life-threatening.Scorpion Capital has previously revealed short positions in multiple pharmaceutical and biotechnology companies, including Transmedics Group Inc (TMDX), Harmony Biosciences (HRMY), Twist Bioscience (TWST), and more.SLNO stock is up by 60% this year and by about 42% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/cleveland-cliffs-enters-multi-year-steel-deals-with-automakers-report/chsPDjERdfH">Cleveland-Cliffs Enters Multi-Year Steel Deals With Automakers, Says Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Soleno Therapeutics Stock Slumps After Scorpion Capital Reveals Short Position: But Retail’s Not Pessimistic Yet

The shortseller alleged several risks associated with Vykat XR, including high risk of pre-diabetes/diabetes, pulmonary edema, and congestive heart failure.

Equity

How Much Upside is Left in Soleno Therapeutics (SLNO)? Wall Street Analysts Think 43.15%

The average of price targets set by Wall Street analysts indicates a potential upside of 43.2% in Soleno Therapeutics (SLNO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Here's Why Momentum in Soleno Therapeutics (SLNO) Should Keep going

Soleno Therapeutics (SLNO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Soleno Therapeutics, Inc. (SLNO) Reports Q2 Loss, Tops Revenue Estimates

Soleno Therapeutics (SLNO) delivered earnings and revenue surprises of +83.02% and +1.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Soleno Therapeutics, Inc. (SLNO) is a Great Momentum Stock: Should You Buy?

Does Soleno Therapeutics, Inc. (SLNO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Can Soleno Therapeutics (SLNO) Climb 33.11% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for Soleno Therapeutics (SLNO) points to a 33.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Here's What Could Help Soleno Therapeutics (SLNO) Maintain Its Recent Price Strength

If you are looking for stocks that are well positioned to maintain their recent uptrend, Soleno Therapeutics (SLNO) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Shares of biopharmaceutical company Soleno Therapeutics, Inc. (SLNO) were in the spotlight on Monday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.soleno.life/news-releases/news-release-details/soleno-therapeutics-announces-vykattm-xr-launch">announced</a> the launch of its VYKAT XR extended-release tablets in the U.S. as a treatment for hyperphagia in patients four years of age and older with Prader-Willi syndrome (PWS).VYKAT XR has now been delivered to the first individuals living with PWS who have been prescribed the medication, the company said.Prader-Willi syndrome is a rare genetic neurodevelopmental disorder caused by an abnormality in the gene expression on chromosome 15, estimated to occur in one in every 15,000 live births.The disorder is defined by hyperphagia, an intense, persistent sensation of hunger, which could be life-threatening.Soleno Therapeutics CEO Anish Bhatnagar said that the drug saw “strong interest” following approval from the U.S. Food and Drug Administration (FDA) in late March.“Our team is fully prepared to meet demand and is well-positioned to execute a successful commercial launch of this first-to-market treatment.”VYKAT XR is the company’s first commercial product. The pills have to be consumed orally once a day.Soleno said the common adverse effects identified in 10% or more individuals receiving the drug include hypertrichosis, edema, hyperglycemia, and rash.On Stocktwits, retail sentiment around Soleno stayed unmoved within ‘bearish’ territory over the past 24 hours, coupled with ‘extremely low’ message volume.<figure class="image"><img style="aspect-ratio:647/150;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_14_at_9_00_06_AM_png_f6762d4e34.webp" alt="SLNO's Sentiment Meter and Message Volume as of 9:00 a.m. ET on April 14, 2025 | Source: Stocktwits" width="647" height="150"><figcaption>SLNO's Sentiment Meter and Message Volume as of 9:00 a.m. ET on April 14, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/SLNO">SLNO stock</a> is up by over 45% year-to-date and by over 72% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/third-harmonic-bio-devises-plan-to-dissolve-company/chfCdnIRba5">Third Harmonic Bio Announces Liquidation Plan: Stock Skyrockets 39% Pre-Market, But Retail’s Shattered</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Global stock market chart and trading board - stock photo

Soleno Launches Pill For Hyperphagia In Prader-Willi Syndrome Patients But Retail’s Unmoved

VYKAT XR has now been delivered to the first individuals living with PWS who have been prescribed the medication, the company said.

Shares of Soleno Therapeutics (SLNO) rocketed nearly 34% in premarket trading on Thursday after the biopharmaceutical company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.soleno.life/news-releases/news-release-details/soleno-therapeutics-announces-us-fda-approval-vykattm-xr-treat">received</a> approval from the Food and Drug Administration (FDA) for its VYKAT XR extended-release tablets.If the pre-market gains are sustained, the stock is headed toward its eight-year highs on a closing basis.In adults, VYKAT XR tablets are used to treat hyperphagia, an intense, persistent sensation of hunger. They are also used to treat children of the age of four or above with Prader-Willi syndrome, a rare genetic neurodevelopmental disorder caused by an abnormality in the gene expression on chromosome 15.PWS is estimated to occur in one in every 15,000 live births.The company expects the drug, the first approved therapy to address hyperphagia in PWS patients, to be available in the U.S. starting April 2025. The tablets have to be consumed orally once every day.CEO Anish Bhatnagar said the approval of VYKAT XR is a significant milestone for Soleno and, most importantly, for the PWS community, who have had no options to treat the most disruptive aspect of this disease.VYKAT XR is the company’s first commercial product.Soleno said the common adverse effects identified in 10% or more individuals receiving the drug include hypertrichosis, edema, hyperglycemia, and rash.On Stocktwits, retail investor sentiment about Soleno jumped further into the ‘extremely bullish’ territory (100/100) accompanied by significant retail chatter over the past 24 hours.<figure class="image"><img style="aspect-ratio:649/149;" src="https://news.stocktwits-cdn.com/Screenshot_2025_03_27_at_7_52_39_AM_png_aa2d4ebc9e.webp" alt="SLNO's Sentiment Meter and Message Volume as of 7:50 a.m. ET on March 27, 2025 | Source: Stocktwits" width="649" height="149"><figcaption>SLNO's Sentiment Meter and Message Volume as of 7:50 a.m. ET on March 27, 2025 | Source: Stocktwits</figcaption></figure>Stocktwits user comments indicated a positive take on the shares.<stembedurl>https://stocktwits.com/Royalty_Ba/message/609389592</stembedurl><stembedurl>https://stocktwits.com/MontanaT/message/609389586</stembedurl><a href="https://stocktwits.com/symbol/SLNO">Soleno shares</a> gained nearly 7% in 2025 and by over 14% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/tsla-stock-faces-more-pressure-from-trump-auto-tariffs/chJcUDRRbE2">Tesla Stock Faces More Pressure As Musk Says Trump Tariffs Will Have An Impact, Retail Clings To Bullish Hopes</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market data with uptrend vector | Illustration Source: Getty Images

Soleno Therapeutics Stock Rockets 34% Pre-Market After FDA Approves Prader-Willi Syndrome Drug: Retail Sentiment Peaks 

The company expects the drug, the first approved therapy to address hyperphagia in PWS patients, to be available in the U.S. starting April 2025.

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

SLNO
Soleno Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SLNO News

SLNO Soleno Therapeutics Inc